CN101248051B - 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法 - Google Patents

制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法 Download PDF

Info

Publication number
CN101248051B
CN101248051B CN2006800178794A CN200680017879A CN101248051B CN 101248051 B CN101248051 B CN 101248051B CN 2006800178794 A CN2006800178794 A CN 2006800178794A CN 200680017879 A CN200680017879 A CN 200680017879A CN 101248051 B CN101248051 B CN 101248051B
Authority
CN
China
Prior art keywords
formula
compound
acid
alkyl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800178794A
Other languages
English (en)
Chinese (zh)
Other versions
CN101248051A (zh
Inventor
D·P·R·施尔斯
A·E·斯塔帕斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Tibotec Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35822492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101248051(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceuticals Ltd filed Critical Tibotec Pharmaceuticals Ltd
Publication of CN101248051A publication Critical patent/CN101248051A/zh
Application granted granted Critical
Publication of CN101248051B publication Critical patent/CN101248051B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN2006800178794A 2005-05-26 2006-05-24 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法 Active CN101248051B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05104531 2005-05-26
EP05104531.8 2005-05-26
US68599305P 2005-05-31 2005-05-31
US60/685,993 2005-05-31
PCT/EP2006/062606 WO2006125809A1 (en) 2005-05-26 2006-05-24 Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino benzonitrile

Publications (2)

Publication Number Publication Date
CN101248051A CN101248051A (zh) 2008-08-20
CN101248051B true CN101248051B (zh) 2013-07-17

Family

ID=35822492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800178794A Active CN101248051B (zh) 2005-05-26 2006-05-24 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法

Country Status (19)

Country Link
US (2) US8101752B2 (enExample)
EP (1) EP1888537B1 (enExample)
JP (2) JP5148483B2 (enExample)
CN (1) CN101248051B (enExample)
AU (1) AU2006251163C1 (enExample)
BR (1) BRPI0611038B8 (enExample)
CA (1) CA2609716C (enExample)
DK (1) DK1888537T3 (enExample)
ES (1) ES2437202T3 (enExample)
HR (1) HRP20131133T1 (enExample)
IN (1) IN2014DN04588A (enExample)
ME (1) ME01612B (enExample)
MX (1) MX2007014881A (enExample)
PL (1) PL1888537T3 (enExample)
PT (1) PT1888537E (enExample)
RS (1) RS53062B (enExample)
RU (1) RU2458056C2 (enExample)
SI (1) SI1888537T1 (enExample)
WO (1) WO2006125809A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2609716C (en) * 2005-05-26 2014-10-14 Tibotec Pharmaceuticals Ltd. Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
EP2825555B1 (en) 2012-03-13 2017-07-12 Octapharma AG Mproved process for production of fibrinogen and fibrinogen produced thereby
CN103058936B (zh) * 2013-01-23 2016-01-06 宁波九胜创新医药科技有限公司 4-[(4-氯-2-嘧啶基)氨基]苯腈的制备方法
CN103193719B (zh) * 2013-04-08 2015-07-22 宁波九胜创新医药科技有限公司 一种4-[(4-羟基-2-嘧啶基)氨基]苯腈的制备方法
CN114933567B (zh) * 2022-04-29 2023-07-11 武汉工程大学 一种2-甲硫基-4-嘧啶酮的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295564A (zh) * 1998-03-27 2001-05-16 詹森药业有限公司 抑制hiv的嘧啶衍生物
CN1322198A (zh) * 1998-11-10 2001-11-14 詹森药业有限公司 抑制hiv复制的嘧啶类
CN1541215A (zh) * 2001-08-13 2004-10-27 ղɭҩҵ���޹�˾ 抑制hiv的嘧啶衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63502B1 (en) * 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
DE3923979A1 (de) 1989-07-20 1991-01-24 Merck Patent Gmbh Verfahren zur herstellung von aromatischen nitrilen
RU2037483C1 (ru) * 1989-07-20 1995-06-19 Мерк Патент Гмбх Способ получения замещенных ароматических нитрилов
SI1225874T1 (sl) * 1999-09-24 2006-06-30 Janssen Pharmaceutica Nv Protivirusne trdne disperzije
ES2559273T3 (es) * 2000-05-08 2016-02-11 Janssen Pharmaceutica Nv Profármacos de pirimidinas que inhiben la replicación del VIH
IL161662A0 (en) * 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
CN101481356B (zh) * 2002-08-09 2012-07-11 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
ES2323178T3 (es) * 2003-09-30 2009-07-08 Janssen Pharmaceutica Nv Compuestos de benzoimidazol.
CA2609716C (en) * 2005-05-26 2014-10-14 Tibotec Pharmaceuticals Ltd. Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295564A (zh) * 1998-03-27 2001-05-16 詹森药业有限公司 抑制hiv的嘧啶衍生物
CN1322198A (zh) * 1998-11-10 2001-11-14 詹森药业有限公司 抑制hiv复制的嘧啶类
CN1541215A (zh) * 2001-08-13 2004-10-27 ղɭҩҵ���޹�˾ 抑制hiv的嘧啶衍生物

Also Published As

Publication number Publication date
CN101248051A (zh) 2008-08-20
ME01612B (me) 2014-09-20
AU2006251163C1 (en) 2012-07-12
JP2008545680A (ja) 2008-12-18
EP1888537B1 (en) 2013-09-11
BRPI0611038B8 (pt) 2022-10-25
HRP20131133T1 (hr) 2014-01-03
BRPI0611038A2 (pt) 2010-08-10
DK1888537T3 (da) 2013-12-09
BRPI0611038B1 (pt) 2022-02-08
JP5580385B2 (ja) 2014-08-27
US20080171878A1 (en) 2008-07-17
RS53062B (sr) 2014-04-30
MX2007014881A (es) 2008-02-15
AU2006251163A1 (en) 2006-11-30
PL1888537T3 (pl) 2014-02-28
US8618291B2 (en) 2013-12-31
ES2437202T3 (es) 2014-01-09
US20120083606A1 (en) 2012-04-05
RU2458056C2 (ru) 2012-08-10
JP2013040194A (ja) 2013-02-28
JP5148483B2 (ja) 2013-02-20
US8101752B2 (en) 2012-01-24
CA2609716C (en) 2014-10-14
CA2609716A1 (en) 2006-11-30
RU2007148968A (ru) 2009-07-10
EP1888537A1 (en) 2008-02-20
WO2006125809A1 (en) 2006-11-30
IN2014DN04588A (enExample) 2015-07-10
PT1888537E (pt) 2013-11-26
AU2006251163B2 (en) 2012-03-08
SI1888537T1 (sl) 2014-01-31
HK1123551A1 (en) 2009-06-19

Similar Documents

Publication Publication Date Title
RU2556986C2 (ru) Способ синтеза диарилпиримидинового ненуклеозидного ингибитора обратной транскриптазы
US20040209901A1 (en) Novel compounds
CN105646372B (zh) 一种2-氨基-4,6-二氯-5-甲酰胺基嘧啶的制备方法
JP5580385B2 (ja) ４−［（１，６−ジヒドロ−６−オキソ−２−ピリミジニル）アミノベンゾニトリルの製造方法
JP2000191647A (ja) Ｎ―（アミノ―４，６―ジハロピリミジン）ホルムアミド類の製造方法
US20060293348A1 (en) Novel compounds
CN110627729B (zh) 2-氨基-6-氯嘌呤及其合成方法、中间物和应用
Hirota et al. A NOVEL SYNTHESIS OF PYRIDO (2, 3‐D) PYRIMIDINES BY REACTION OF URACILS WITH 6‐AMINOURACILS VIA PYRIMIDINE‐TO‐PYRIDINE TRANSFORMATION
CN110396079A (zh) 一种氯虫苯甲酰胺中间体的制备方法及其应用
CN115141180A (zh) 一种鲁索替尼中间体的制备方法
EP1046635A1 (en) Process for preparing an aromatic compound substituted by a tertiary nitrile
JPH0549666B2 (enExample)
AU656252B2 (en) A process for preparing 4,6-dialkoxy-pyrimidines
WO2013178020A1 (zh) 一种制备依曲韦林的方法及其中间体
JP2001072667A (ja) ４，６−ジクロロ−５−フルオロピリミジンを製造する方法
SK282077B6 (sk) Spôsob prípravy 2-amino-4,6-dichlórpyrimidínu
WO2023104195A1 (zh) 一种异噻唑并[5,4-d]嘧啶类IRAK4抑制剂的制备方法
CN109232441B (zh) 一种4-氨基-2,6-二甲氧基嘧啶的制备方法
WO2014068588A2 (en) Process for the synthesis of etravirine and its intermediates
JPS59227866A (ja) ２，４−ジアルコキシ−６−ヒドロキシピリミジン類の製造法
CN107266426A (zh) 2‑氨烃基嘧啶类化合物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1123551

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: TIBOTEC PHARM LTD.

Free format text: FORMER NAME: TIBOTEC NV

CP01 Change in the name or title of a patent holder

Address after: The Irish Village

Patentee after: Tibotec Pharm Ltd.

Address before: The Irish Village

Patentee before: Tibotec NV

ASS Succession or assignment of patent right

Owner name: JANSSEN R + D IRELAND

Free format text: FORMER OWNER: TIBOTEC PHARM LTD.

Effective date: 20131106

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20131106

Address after: Kirk County, Ireland

Patentee after: Tibotec Pharm Ltd.

Address before: The Irish Village

Patentee before: Tibotec Pharm Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1123551

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: IRELAND JANSSEN R + D COMPANY

Free format text: FORMER OWNER: JANSSEN R + D IRELAND

Effective date: 20150728

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150728

Address after: The Irish Village

Patentee after: Ireland Jansen scientific company

Address before: Kirk County, Ireland

Patentee before: Tibotec Pharm Ltd.